Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|April 11, 2017
TrialScope Launches Global Compliance Tool
Advertisement
Introduces new solution to target multi-billion dollar global disclosure risks
Jersey City, NJ –
ATLAS enables sponsors to quickly ensure that their trials are compliant by combining key information from all sites in the trial into one, easily accessible view.
ATLAS addresses the issues within global disclosure and compliance that pose the greatest challenges to trial sponsors, including:
- Identifying and managing local or regional disclosure requirements
- Ensuring the sponsor’s disclosure policies are in effect
- Tracking disclosure performance against requirements and policies
ATLAS is designed to support sponsors of all sizes, providing critical compliance and disclosure oversight through an easy-to-implement SaaS solution. For sponsors who are managing multiple sites in multiple geographies, ATLAS ensures all compliance and disclosure requirements are met, eliminating potential costs and delays in the trial.
Mark Heinold, TrialScope CEO, noted, “ATLAS and the expansion of TrialScope’s portfolio of transparency and compliance solutions, reflect two shifts in the marketplace: increased complexity and risk and a growing need for broader, more meaningful views of global transparency initiatives. We are committed to supporting disclosure and transparency efforts that ultimately provide a better understanding of clinical research around the world.”
Clinical trial sponsors seeking more information about TrialScope’s ATLAS Global Compliance can
About TrialScope
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5